Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 113Breast Neoplasms 113Ovarian Neoplasms 69Triple Negative Breast Neoplasms 56Endometrial Neoplasms 42Fallopian Tube Neoplasms 40Squamous Cell Carcinoma of Head and Neck 39Lung Neoplasms 38Neoplasm Metastasis 35Stomach Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 27Neoplasms 27Esophageal Neoplasms 22Esophageal Squamous Cell Carcinoma 21Head and Neck Neoplasms 16Uterine Cervical Neoplasms 15Carcinoma, Ovarian Epithelial 15Carcinoma 15Colorectal Neoplasms 14Carcinoma, Squamous Cell 11Adenocarcinoma 10Small Cell Lung Carcinoma 9Adenocarcinoma Of Esophagus 9Peritoneal Neoplasms 8Oropharyngeal Neoplasms 8Melanoma 8Carcinoma, Transitional Cell 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Mouth Neoplasms 7

Interventions

pembrolizumab 1Taxes 1Sirolimus 1Panitumumab 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Erythema × Paclitaxel × 1 year × Clear all
NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
42 enrolled
Breast

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡